Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Neutral 0

SNN vs. BSX: Which Stock Is the Better Value Option?

AI-generated analysis

πŸ“Š Smith & Nephew (SNN) receives a #2 (Buy) Zacks Rank due to strong earnings estimate revision trends.

πŸ’Ή Boston Scientific (BSX) currently holds a #4 (Sell) Zacks Rank, indicating weaker analyst outlook improvements.

βš–οΈ SNN carries a forward P/E ratio of 13.52 compared to BSX's higher rate of 16.84.

πŸ“ˆ The Price/Earnings-to-Growth (PEG) ratio for SNN is 0.96 versus 1.04 for Boston Scientific.

🏦 Smith & Nephew trades at a Price/Book value of 2.48, while Boston Scientific stands at 3.24.

🌟 Based on these metrics, SNN earns an A grade in the Value category of Style Scores.

⚠️ Boston Scientific receives a lower C grade within the same Value style scoring system.

πŸ’‘ Analysts conclude that Smith & Nephew represents the superior value option right now.

πŸ₯ Both companies operate within the Medical Products sector as well-known equities in this space.

πŸ“‰ Zacks Rank methodology specifically favors stocks showing positive earnings estimate revision activity.

πŸ” Style Scores highlight companies with specific traits beyond just traditional valuation metrics.

πŸ“ The analysis suggests investors should feel more comfortable with SNN's improving analyst outlook.

🎯 Forward P/E and PEG ratios are cited as key factors contributing to the valuation difference.

Bullish Signals
  • Smith & Nephew (SNN) holds a superior Zacks Rank of #2 (Buy), indicating more impressive earnings estimate revision trends compared to Boston Scientific.
  • SNN carries a Value grade of A versus BSX's C, based on favorable metrics like a lower forward P/E ratio of 13.52 and a PEG ratio of 0.96.
Risk Factors
  • Boston Scientific currently holds a Zacks Rank of #4 (Sell), indicating negative earnings estimate revision trends compared to competitors.
  • BSX carries a significantly higher forward P/E ratio of 16.84 versus Smith & Nephew's 13.52, suggesting it may be overvalued relative to peers.
  • The company's Price-to-Book (P/B) ratio is elevated at 3.24 compared to SNN's 2.48, raising concerns about whether the market value exceeds the underlying asset value.
  • BSX receives a Value grade of C from the Style Scores system, reflecting weaker valuation fundamentals and financial traits.
Full Analysis
Smith & Nephew plc is identified as the better value option compared to Boston Scientific Corporation based on Zacks Investment Research analysis. The primary differentiator noted is the earnings estimate revision trend, which gives Smith & Nephew a Zacks Rank of #2 (Buy) versus a Rank of #4 (Sell) for Boston Scientific, indicating a more positive analyst outlook for SNN. This assessment is supported by specific valuation metrics where Smith & Nephew displays superior value characteristics; it boasts a forward price-to-earnings ratio of 13.52 compared to Boston Scientific's 16.84, and a lower price-to-book ratio of 2.48 versus 3.24. Additionally, the price-to-earnings-to-growth ratio for Smith & Nephew stands at 0.96, while Boston Scientific is at 1.04. These combined metrics contribute to Smith & Nephew receiving an A grade in the Value category of the Style Scores system, whereas Boston Scientific receives a C grade, leading analysts to conclude that Smith & Nephew is the superior choice for value investors currently.